Lenalidomide: Targeted anemia therapy for myelodysplastic syndromes

Alan F. List, Amanda F Baker, Sylvan Green, William Bellamy

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Lenalidomide, an IMiD® drug (a novel type of immunomodulating drug) was recently approved by the US Food and Drug Administration for the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS) and interstitial deletions of chromosome 5q [del(5q)]. This review examines the clinical experience from the MDS-001 and MDS-003 clinical trials that led to this approval, the results of biological correlates supporting the targets of drug action, and the results from a non-del(5q) multicenter study (MDS-002). Lenalidomide treatment resulted in both erythroid and cytogenetic responses in the majority of patients with del(5q), accompanied by reductions in inflammatory cytokine generation and marrow microvessel density and improvement in primitive hematopoietic progenitor recovery. Central pathology review showed that resolution of cytologic dysplasia was common in patients with del(5q) but was infrequent in erythroid-responding patients without the chromosome 5 deletion. These findings indicate that lenalidomide promotes erythropoiesis in lower-risk MDS, with two apparently distinct mechanisms of action: suppression of the ineffective del(5q) clone and promotion of effective erythropoiesis in non-del(5q) MDS progenitors. These studies identified lenalidomide as a highly active erythropoietic- and cytogenetic-remitting agent in lower-risk MDS patients who otherwise would not be expected to benefit from recombinant erythropoietin therapy. The most common adverse reactions include dose-dependent neutropenia and thrombocytopenia that are more pronounced in patients with del(5q) in whom early suppression of the clone is expected.

Original languageEnglish (US)
Pages (from-to)4-11
Number of pages8
JournalCancer Control
Volume13
Issue numberSUPPL.
StatePublished - 2006

Fingerprint

Myelodysplastic Syndromes
Anemia
Chromosome Deletion
Erythropoiesis
Cytogenetics
Therapeutics
Clone Cells
Pharmaceutical Preparations
Chromosomes, Human, Pair 5
United States Food and Drug Administration
Erythropoietin
Microvessels
lenalidomide
Neutropenia
Thrombocytopenia
Multicenter Studies
Bone Marrow
Clinical Trials
Pathology
Cytokines

ASJC Scopus subject areas

  • Oncology

Cite this

List, A. F., Baker, A. F., Green, S., & Bellamy, W. (2006). Lenalidomide: Targeted anemia therapy for myelodysplastic syndromes. Cancer Control, 13(SUPPL.), 4-11.

Lenalidomide : Targeted anemia therapy for myelodysplastic syndromes. / List, Alan F.; Baker, Amanda F; Green, Sylvan; Bellamy, William.

In: Cancer Control, Vol. 13, No. SUPPL., 2006, p. 4-11.

Research output: Contribution to journalArticle

List, AF, Baker, AF, Green, S & Bellamy, W 2006, 'Lenalidomide: Targeted anemia therapy for myelodysplastic syndromes', Cancer Control, vol. 13, no. SUPPL., pp. 4-11.
List, Alan F. ; Baker, Amanda F ; Green, Sylvan ; Bellamy, William. / Lenalidomide : Targeted anemia therapy for myelodysplastic syndromes. In: Cancer Control. 2006 ; Vol. 13, No. SUPPL. pp. 4-11.
@article{41fa9faab37f4359ad23def00c126dec,
title = "Lenalidomide: Targeted anemia therapy for myelodysplastic syndromes",
abstract = "Lenalidomide, an IMiD{\circledR} drug (a novel type of immunomodulating drug) was recently approved by the US Food and Drug Administration for the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS) and interstitial deletions of chromosome 5q [del(5q)]. This review examines the clinical experience from the MDS-001 and MDS-003 clinical trials that led to this approval, the results of biological correlates supporting the targets of drug action, and the results from a non-del(5q) multicenter study (MDS-002). Lenalidomide treatment resulted in both erythroid and cytogenetic responses in the majority of patients with del(5q), accompanied by reductions in inflammatory cytokine generation and marrow microvessel density and improvement in primitive hematopoietic progenitor recovery. Central pathology review showed that resolution of cytologic dysplasia was common in patients with del(5q) but was infrequent in erythroid-responding patients without the chromosome 5 deletion. These findings indicate that lenalidomide promotes erythropoiesis in lower-risk MDS, with two apparently distinct mechanisms of action: suppression of the ineffective del(5q) clone and promotion of effective erythropoiesis in non-del(5q) MDS progenitors. These studies identified lenalidomide as a highly active erythropoietic- and cytogenetic-remitting agent in lower-risk MDS patients who otherwise would not be expected to benefit from recombinant erythropoietin therapy. The most common adverse reactions include dose-dependent neutropenia and thrombocytopenia that are more pronounced in patients with del(5q) in whom early suppression of the clone is expected.",
author = "List, {Alan F.} and Baker, {Amanda F} and Sylvan Green and William Bellamy",
year = "2006",
language = "English (US)",
volume = "13",
pages = "4--11",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "SUPPL.",

}

TY - JOUR

T1 - Lenalidomide

T2 - Targeted anemia therapy for myelodysplastic syndromes

AU - List, Alan F.

AU - Baker, Amanda F

AU - Green, Sylvan

AU - Bellamy, William

PY - 2006

Y1 - 2006

N2 - Lenalidomide, an IMiD® drug (a novel type of immunomodulating drug) was recently approved by the US Food and Drug Administration for the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS) and interstitial deletions of chromosome 5q [del(5q)]. This review examines the clinical experience from the MDS-001 and MDS-003 clinical trials that led to this approval, the results of biological correlates supporting the targets of drug action, and the results from a non-del(5q) multicenter study (MDS-002). Lenalidomide treatment resulted in both erythroid and cytogenetic responses in the majority of patients with del(5q), accompanied by reductions in inflammatory cytokine generation and marrow microvessel density and improvement in primitive hematopoietic progenitor recovery. Central pathology review showed that resolution of cytologic dysplasia was common in patients with del(5q) but was infrequent in erythroid-responding patients without the chromosome 5 deletion. These findings indicate that lenalidomide promotes erythropoiesis in lower-risk MDS, with two apparently distinct mechanisms of action: suppression of the ineffective del(5q) clone and promotion of effective erythropoiesis in non-del(5q) MDS progenitors. These studies identified lenalidomide as a highly active erythropoietic- and cytogenetic-remitting agent in lower-risk MDS patients who otherwise would not be expected to benefit from recombinant erythropoietin therapy. The most common adverse reactions include dose-dependent neutropenia and thrombocytopenia that are more pronounced in patients with del(5q) in whom early suppression of the clone is expected.

AB - Lenalidomide, an IMiD® drug (a novel type of immunomodulating drug) was recently approved by the US Food and Drug Administration for the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS) and interstitial deletions of chromosome 5q [del(5q)]. This review examines the clinical experience from the MDS-001 and MDS-003 clinical trials that led to this approval, the results of biological correlates supporting the targets of drug action, and the results from a non-del(5q) multicenter study (MDS-002). Lenalidomide treatment resulted in both erythroid and cytogenetic responses in the majority of patients with del(5q), accompanied by reductions in inflammatory cytokine generation and marrow microvessel density and improvement in primitive hematopoietic progenitor recovery. Central pathology review showed that resolution of cytologic dysplasia was common in patients with del(5q) but was infrequent in erythroid-responding patients without the chromosome 5 deletion. These findings indicate that lenalidomide promotes erythropoiesis in lower-risk MDS, with two apparently distinct mechanisms of action: suppression of the ineffective del(5q) clone and promotion of effective erythropoiesis in non-del(5q) MDS progenitors. These studies identified lenalidomide as a highly active erythropoietic- and cytogenetic-remitting agent in lower-risk MDS patients who otherwise would not be expected to benefit from recombinant erythropoietin therapy. The most common adverse reactions include dose-dependent neutropenia and thrombocytopenia that are more pronounced in patients with del(5q) in whom early suppression of the clone is expected.

UR - http://www.scopus.com/inward/record.url?scp=33846449862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846449862&partnerID=8YFLogxK

M3 - Article

C2 - 17242661

AN - SCOPUS:33846449862

VL - 13

SP - 4

EP - 11

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - SUPPL.

ER -